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Abstract. Prognostic markers of compensated cirrhosis should mainly investigate factors involved with progression to decompen-
sation because death in cirrhosis is related with decompensation. Portal hypertension plays a crucial role in the pathophysiology of
most complications of cirrhosis. Accordingly, HVPG monitoring has strong prognostic value. An HVPG 10 mmHg determines
a significantly higher risk of developing decompensation. Esophageal varices also can develop when the HVPG is 10 mmHg,
although an HVPG  12 mmHg is required for variceal bleeding to occur. Monitoring the changes induced by the treatment
of portal hypertension on HVPG, provides strong prognostic information. In compensated cirrhosis hemodynamic response is
appropriate when the HVPG decreased to< 10 mmHg or by> 10% from baseline, because the incidence of complications such
as bleeding or ascites significantly decrease when these targets are achieved. Whether serum markers, such as the FibroTest,
they, may be valuable to predict decompensation should be established. Transient Elastography is a promising technique that
has shown an excellent accuracy to detect severe portal hypertension. However, whether it can adequately determine clinically
significant portal hypertension, and risk of developing varices and decompensation, should be established. Magnetic Resonance
Elastography is also promising.
Keywords: Compensated cirrhosis, Prognostic markers, hepatic venous pressure gradient, HVPG monitoring
1. Introduction
The natural history of cirrhosis involves an early
asymptomatic stage or “compensated”,which over time
progresses to a symptomatic or “decompensated” stage,
identified by the presence of complications of cirrhosis
such as ascites, variceal bleeding or encephalopathy [1].
Furthermore, two distinct stages can be differentiated
in the compensated phase of cirrhosis. The first stage is
characterized by the absence of esophageal varices and
is associated with a mortality of less than 1%, while the
second stage is characterized by the presence of varices
and is associated with a mortality of 3.4% per year [1].
The course of cirrhosis progressively involves an in-
crease in portal pressure, and worsening of hepatocel-
lular function, which ultimately leads to the develop-
ment of some of the complications defining the transi-
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tion from the compensated to the decompensated phase
of the disease [2]. A patient with compensated cirrho-
sis can have virtually the same survival and causes of
death than general population, while a decompensated
patient has a median survival of less than 2 years. Pa-
tients with compensated cirrhosis die mostly after tran-
sition to a decompensated stage, and the annual prob-
ability of moving from compensated to decompensat-
ed cirrhosis is around 15% of cases [1–3]. In keeping
with this, prognostic markers of the compensated stage
of cirrhosis should mainly investigate factors involved
with progression to decompensation, because death in
cirrhosis is clearly related to the development of de-
compensation. On the other hand, prognostic markers
of the decompensated stage should also assess factors
determining mortality.
2. Prognostic assessment in pre-primary
prophylaxis
Portal hypertension, usually estimated by the hepatic
venous pressure gradient or HVPG, plays a crucial role
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in the pathophysiology of most complications associ-
ated with cirrhosis [4]. Different studies have demon-
strated the prognostic value of HVPG monitoring [5].
It has been shown that the risk of developing varices
is significantly higher when the HVPG is  10 mmHg
and that patients with an HVPG  10 mmHg have a
significantly higher probability of developing decom-
pensated cirrhosis [6,7]. The likelihood of decompen-
sation, during a median of 4 years of follow-up, is <
10% in patients with an HVPG < 10 mmHg and is of
40% in patients with an HVPG  10 mmHg [7]. In
addition to the qualitative value of HVPG (presence or
absence of an HVPG  10 mm Hg), the quantitative
degree of portal hypertension is also relevant because
it has been suggested that for each 1 mmHg increase in
HVPG there is an 11% higher risk of clinical decom-
pensation [7].
The assessment of HVPG allows the distinction of
two phases with different prognostic implications in
compensated cirrhosis. There is an initial phase with
moderate portal hypertension indicated by an HVPG >
6mmHg but < 10 mmHg [6]. In this phase, patients
have a very low risk of developing decompensation of
cirrhosis. In a subsequent phase, portal hypertension
progress to severe or clinically significant which is de-
fined by an HVPG  10 mmHg that determines a sig-
nificantly higher risk of decompensation of cirrhosis [7,
8]. It has been observed that with disease progression,
up to 41% of patients who initially had mild portal hy-
pertension (with HVPG < 10mmHg) develop clinical-
ly significant portal hypertension (with HVPG  10
mmHg) after 24 months of follow up [9].
Esophageal varices can develop when the HVPG is
 10 mmHg [8]. However, an HVPG  12 mmHg
is usually required for variceal bleeding to occur, and
it has been demonstrated that the reduction of HVPG
below this threshold value virtually abolishes the risk
of bleeding [10].
Monitoring the changes induced by the treatment of
portal hypertension on HVPG, provides strong prog-
nostic information [5,11]. A relevant number of stud-
ies, mainly dealing with patients treated to prevent
variceal rebleeding, have shown that the hemodynam-
ic response is appropriate when the HVPG decreased
to < 12 mmHg or > 20% from to baseline [8,12,
13]. Patients who achieve these targets have a bleed-
ing risk significantly reduced to below 10–15% [14].
Hemodynamic response is also associated with a low-
er incidence of other complications of portal hyper-
tension such as ascites, spontaneous bacterial peritoni-
tis and hepatorenal syndrome, and with increased sur-
vival [15–17]. However, recent studies suggest that the
diagnostic accuracy of hemodynamic monitoring can
be improved, mainly in compensated cirrhosis [14,18].
Although the negative predictivevalue of this technique
is very high (around 90%), positive predictive value is
modest, especially in primary prophylaxis [19]. In pri-
mary prophylaxis the majority of patients (up to 60%)
do not have an HVPG reduction  20% from baseline
with β-blockers, but despite it variceal bleeding occurs
in few patients (around 15%) [8,20,21]. A recent study
shows that, in this setting, a cut-off reduction > 10% in
HVPG can improve the diagnostic accuracy achieved
using the cut-off of 20% decrease to define response,
substantially increasing specificity [22]. In that study,
by using the 10% target, the proportion of nonrespon-
ders decreased markedly, from 66% to 36%, and a no-
table increase in the rate of first bleeding among non-
responders was also observed, from 27% to 46%, thus
improving the positive predictive value [22]. These
results clearly suggest a relevant improvement in the
diagnostic accuracy of HVPG monitoring in primary
prophylaxis using the 10% target to define response.
In addition to the prognostic value for bleeding,mon-
itoring of changes on HVPG also provides relevant
prognostic information on the probability of develop-
ing ascites in patients with compensated cirrhosis at
high risk of decompensation as indicated by a baseline
HVPG > 10 mmHg [7]. A recent study showed that
once clinically significant portal hypertension has been
reached, it is still possible to reduce the probability of
developing ascites by achieving a decrease in HVPG
 10% from baseline [23]. This represents a relevant
issue because ascites is the most frequent complication
of cirrhosis and is often the first decompensation to ap-
pear. On the other hand, that study showed that when
such a reduction in HVPG was not achieved, ascites
developed in the majority of patients (up to 90%) [23].
Several studies have already suggested that, even in ear-
lier stages of cirrhosis with compensated disease and
moderate portal hypertension with HVPG > 6 mmHg
and absence of varices, a 10% threshold may be the
best cutoff to predict the development of clinical de-
compensation [6,7].
Recent studies have also shown that the evaluation
of acute response to administration of intravenous beta-
blockers in a single hemodynamic study, can accurately
predict the long-termoutcome [22,24]. As compared to
nonresponders, acute responders had a lower probabil-
ity of a first bleeding, a lower risk of developing ascites
during the follow-up and better survival [22]. This is a
particularly important issue because assessing response
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in a single hemodynamic study, not only eliminates the
need for a second invasive procedure, but also allows
an immediate rescue therapy for nonresponders. It is
possible that these factors will improve the diagnostic
yield of hemodynamic monitoring and its applicability
in clinical practice.
In addition toHVPG monitoring, different predictors
of clinical decompensation related with the severity of
portal hypertension and liver insufficiency have been
identified. A recent study in compensated patients with
hepatitis C virus (both stage 1 and stage 2), identified
the presence of esophageal varices and bilirubin as the
only independent predictors of clinical decompensa-
tion [25]. Child–Pugh score and MELD score have
been predictors in compensated patients in some stud-
ies [25,26]. In another study, in compensated patients
with cirrhosis of different etiologies and portal hyper-
tension, but without varices, HVPG, MELD, and albu-
min were independent predictors of the development
of clinical decompensation [7]. However, HVPG had
a predominant predictive role and was the most robust
predictor of clinical decompensation,with a greater dis-
criminative ability in the prediction of decompensation,
which will ultimately determine survival.
Because disease-related complications of cirrhosis
are mediated by the development and progression of
hepatic fibrosis, a variety of serum markers have been
developed for identifying patients who are at risk for
clinically significant hepatic fibrosis. The practical ad-
vantages of serum fibrosis markers include their non-
invasiveness, potential for widespread availability, and
reproducibility. Among them, one of the most widely
used and validated is the FibroTest [27,28]. Several
independent and combined analyses have demonstrat-
ed excellent diagnostic performance for the detection
of histological stage F4 fibrosis [27,28]. However, it
is less accurate in detecting the presence of intermedi-
ate stages of fibrosis as compared to the detection of
cirrhosis [28]. There is also a significant correlation
between FibroTest values and HVPG values, but this
correlation is weaker in patients with cirrhosis [27]. Al-
though the FibroTest value was significantly higher in
patients with severe portal hypertension, the area under
the receiver operating characteristic curve for the diag-
nosis of severe portal hypertension was only 0.79 [27].
Thus, other studies are needed to confirm these results,
especially in patients with compensated cirrhosis [29].
Other serum markers such as laminin levels or serum
hyaluronic acid concentrations have shown acceptable
positive predictive value for the prediction of severe
portal hypertension, but poor negative predictive val-
ue [30,31]. These markers cannot be currently used to
detect the presence of severe portal hypertension [29].
Transient elastography has shown an excellent ac-
curacy for detecting cirrhosis [32] with sensitivity and
specificity values approaching 90% [33,34]. For the de-
tection of hepatic fibrosis between stages 2–4, however,
its sensitivity and specificity are markedly reduced [33,
34]. Moreover, its accuracy is diminished when obe-
sity and narrow rib interspaces are encountered [35].
Transient elastography has also shown an excellent ac-
curacy for detecting severe portal hypertension with an
HVPG above 10 to 12 mmHg [36–38]. However, the
correlation with HVPG was less strong in patients with
an HVPG value above 10 or 12 mm Hg [36–38]. Tran-
sient elastography has been more accurate than serum
markers for detection of cirrhosis [39]. This suggests
that it may be useful for determining the presence of
clinically significant portal hypertension, with risk of
developing esophageal varices and decompensation.
Additional large-scale prospective studies are need-
ed to further define the role of Transient elastography
for diagnosis and management of severe portal hyper-
tension in compensated cirrhosis.
Magnetic resonance elastography has demonstrated
feasibility and diagnostic accuracy in detecting hep-
atic fibrosis in initial prospective studies [40,41]. As
with Transient elastography, the detection of cirrho-
sis by magnetic resonance elastography is highly ac-
curate with sensitivity and specificity values exceeding
90% [40,41]. This technique is not significantly affect-
ed by obesity or rib interspace width [39]. However,
its correlation with the HVPG should be established.
3. Prognostic assessment in primary prophylaxis
Gastroesophageal varices are the most relevant por-
tosystemic collaterals because their rupture results in
variceal hemorrhage, the most common lethal com-
plication of cirrhosis. Gastroesophageal varices are
present in approximately 50% of patients with cirrho-
sis [42]. Their presence correlates with the severity
of liver disease: while only 40% of Child A patients
have varices, they are present in 85% of Child C pa-
tients [42,43]. Variceal hemorrhage occurs at a year-
ly rate of 5%–15%, and the most important predictor
of hemorrhage is the size of varices, with the highest
risk of first hemorrhage (15% per year) occurring in
patients with large varices [44]. Other predictors of
hemorrhage are decompensated cirrhosis (Child B/C)
and the endoscopic presence of red wale marks [44].
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In patients with cirrhosis the incidence of esophageal
varices increases by nearly 5% per year, and the rate
of progression from small to large varices is approxi-
mately 5 to 10 % per year [6,45,46]. Practice guide-
lines recommend screening for varices in all patients
with cirrhosis because nonselective beta-blockers and
band ligation reduce the risk of first bleeding by 50%
in patients with medium or large varices [47,48]. Prog-
nostic markers in this setting should investigate factors
indicating risk of varices (or large varices) and factors
indicating risk of bleeding among those with varices.
3.1. Detection of varices and prognostic markers for
varices
At present, upper gastrointestinal endoscopy is
the gold standard for determining the presence of
varices [47]. This technique is uncomfortable and inva-
sive for patients and is costly and time-consuming, and
it has been shown that there is interobserver variability
as high as 30% for the detection of small esophageal
varices. Moreover, since the point prevalence of medi-
um/large varices is approximately 15%–25% [42], the
majority of subjects undergoing screening endoscopy
either do not have varices or have varices that do
not require prophylactic therapy. Taking into account
these issues, numerous non-invasive methods alterna-
tives to endoscopy have been studied for determining
the presence of varices, including biochemical and ul-
trasound methods, computed tomography (CT) scan-
ning, video capsule endoscopy and spleen magnetic
resonance imaging. Among them, video capsule en-
doscopy appears to be a very promising tool for the
detection of esophageal varices. Video capsule en-
doscopy has been compared to conventional upper en-
doscopy in several studies [49–53]. A significant cor-
relation has been found between capsule and standard
endoscopy for the detection of varices. The sensitivity
of capsule endoscopy ranged from 68% to 100% with
a specificity ranging from 88% to 100% [49–53]. For
the detection of large varices, the sensitivity was 78%
with a specificity of 96% [52].
Some simple non-invasive methods may have a val-
ue as first line screening for esophageal varices. The
diagnostic value of platelet count has been extensively
studied, and a low platelet count has been repeated-
ly found to be related to the presence of esophageal
varices [39,46,54–56]. However, the optimal thresh-
old varies markedly from study to study, and its diag-
nostic value in patients with compensated cirrhosis has
been questioned [57]. Some simple serumnon-invasive
markers such as the Lok index, the Forns’ index or
the platelet count/spleen diameter ratio have shown a
good performance for diagnosis varices. Remarkably,
in a recent large-scale multicenter study a combination
of a Lok index (cutoff 1.5) and a Forns’ index (cutoff
8.8) had a high negative predictive value for excluding
presence of clinically relevant varices that would ben-
efit from primary prophylaxis (large varices or small
varices with red signs or in Child–Pugh class C pa-
tients) [58]. The platelet count/spleen diameter ratio is
a promising index recently proposed, which has shown
a 100% negative predictive value for excluding any
grade varices [59]. However, the performance charac-
teristics of the test in a following validation study were
lower than in the original report [60]. Two small studies
have also suggested that the FibroTest may be valuable
for excluding presence of large varices [39,61]. De-
spite its excellent accuracy for detecting cirrhosis, tran-
sient elastography seems less sensitive for esophageal
varices and did not perform better than serum indexes
for both the detection of varices and large varices in a
recent study [39].
Despite being very promising, at present, the predic-
tive accuracy of such noninvasivemarkers is still unsat-
isfactory and additional large-scale prospective studies
are needed to define the real role of these non-invasive
markers for diagnosis and grading of varices. Until then
these noninvasive markers should not dictate which pa-
tients should or should not be screened for esophageal
varices by endoscopy [47,48]. On the other hand, it
should be keep in mind that varices may appear when
HVPG increases above 10 mm Hg [6,8], according-
ly patients with HVPG bellow 10 mmHg do not need
endoscopy to assess the development of varices.
3.2. Prognostic markers of risk of bleeding in patients
with varices
Once developed,varices usually increase in size from
small to large before they eventually rupture and bleed.
The reported rate of progression is heterogeneous (5–
30%per year) [45,62,63]. The factor that has beenmost
consistently associated with variceal progression is liv-
er failure, as assessed by Child-Pugh class [45,62,63].
Other factors include alcoholic aetiology of cirrhosis
and presence of red wale markings at the varices [45,
62]. Changes inHVPG (either “spontaneous” or caused
by therapy) are usually accompanied by parallel varia-
tions in the size of the oesophageal varices, which are
significantly reduced when HVPG decreases below 12
mmHg [8].
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In patients with cirrhosis the overall incidence of
variceal bleeding is about 4% per year. This risk in-
creases to 15% per year in patients with medium–large
varices [64]. The most important predictive factors re-
lated to the risk of bleeding are variceal size, Child-
Pugh class and presence of red signs [44]. In addi-
tion, many studies have shown that variceal bleeding
only occurs if the HVPG reaches a threshold value of
12 mmHg [5,8,10]. Varices do not develop until the
HVPG increases up to 10 mmHg [6], and it should
be of at least 12 mmHg for the appearance of variceal
bleeding [8,10]. Longitudinal studies have demonstrat-
ed that if HVPG decreases below 12 mmHg by means
of treatment or spontaneously due to an improvement
in liver disease, variceal bleeding is totally prevented
and varices may decrease in size [8]. Even if this tar-
get is not achieved, a 20% decrease in portal pressure
from baseline levels (or greater) also offers a marked
protection from variceal bleeding [5,12,13].
Patients with medium to large varices should be con-
sidered for prophylactic treatment of variceal bleed-
ing [47,48]. It is well established that “small” varices
with red signs or in Child-Pugh C class patients have
a bleeding risk similar to that of large varices [44].
In keeping with this, it is currently recommended that
these high risk varices should also receive prophylactic
treatment [47,48]. Furthermore, β-blockers may re-
duce the rate of progression from small to large varices,
and decrease the incidence of variceal bleeding in pa-
tients with small varices [63].
Longitudinal studies have demonstrated that a de-
crease in HVPG to < 12 mmHg essentially eliminates
the risk of bleeding and improves survival [8], while
reductions > 20% from baseline or even > 10% from
baseline significantly decrease the risk of first variceal
bleeding [20–22], Whether or not HVPG monitoring
may be useful to guide therapy is currently under in-
vestigation.
4. Implications in future research in this area
HVPG-monitoring provides important prognostic in-
formation that can help to improve the management
of compensated cirrhosis offering different therapeutic
targets. In a large multicenter study β-blockers were
not useful to prevent the development of varices in
compensated cirrhosis with early portal hypertension
(HVPG > 5 mmHg) [6]. However, whether HVPG-
guided therapy may be useful to prevent decompensa-
tion of cirrhosis with clinically significant portal hy-
pertension (HVPG  10 mmHg) at high risk of devel-
oping complications of portal hypertension should be
investigated. Future studies should assess whether in
these high-risk patients, β-blockers alone or combined
with other drugs in hemodynamic non-responders to
β-blockers may be useful to prevent decompensation.
In the genesis and maintenance of portal hyperten-
sion associatedwith cirrhosis, twomechanisms act syn-
ergistically [4]. Initially, there is an increased hep-
atic vascular resistance due to the disruption of liv-
er architecture inherent to cirrhosis but also due, in
part, to an increased hepatic vascular tone caused by
the contraction of portal myofibroblasts and hepatic
stellate cells [65]. With the progression of the dis-
ease, splanchnic vasodilatation develop and lead an in-
creased splanchnic blood flow which maintains and ag-
gravates portal hypertension [66]. β-blockers act on
this second mechanism, decreasing portal pressure by
a reduction of splanchnic blood flow as a result of
drug-induced splanchnic vasoconstriction [67]. How-
ever, in early stages of portal hypertension (HVPG <
10 mmHg), intrahepatic vasoconstriction may be the
main mechanism that determines portal hypertension,
while splanchnic vasodilatation may not yet be fully
developed, which means less potential for vasocon-
strictors [68]. This suggests that hepatic vasodilators,
which may reduce portal pressure by decreasing intra-
hepatic vascular resistance, can be more effective in
early stages of cirrhosis which should also be assessed
in future studies.
Whether or not non-invasive methods to detect clin-
ically significant portal hypertension may be useful in
the management of patients with compensated cirrho-
sis, with or without varices, should also be investigated
in future studies.
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